LeMaitre Vascular, Inc. reported $262M of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $262M (to Q2 2026). Net income: $66M, trailing twelve months to Q2 2026. Free cash flow: $74M, trailing twelve months to Q2 2026. Operating margin: 30%, trailing twelve months to Q2 2026.

LMATLeMaitre Vascular, Inc.

Healthcare

$84.41-2.1% 1Y

$84.41

$78.6652 weeks$117.10

LMAT as reported

LeMaitre Vascular, Inc. reported $262M of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed.

$262M

Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before

Net income: $66M
Net income · +39% year on year · trailing twelve months to Q2 2026
Free cash flow: $74M
Free cash flow · +41% year on year · trailing twelve months to Q2 2026
Operating margin: 30%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for LMAT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$262M	+12%	Q2 2026
Net income	$66M	+39%	Q2 2026
EPS	$2.85	+39%	Q2 2026
Gross margin	73%	n/a	Q2 2026
Operating margin	30%	n/a	Q2 2026
Net margin	25%	n/a	Q2 2026
ROE	15%	n/a	Q2 2026
ROA	9.6%	n/a	Q2 2026
ROIC	27%	n/a	Q2 2026
Free cash flow	$74M	+41%	Q2 2026
P/E	29.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.